Auris Medical
Cochlear therapies

Innovative Treatments for Inner Ear Disorders

First Half 2019 Financial Results & Business Update

August 15, 2019

NASDAQ: EARS

Forward-looking Statements

This presentation and the accompanying oral commentary may contain statements may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” or the negative of these terms and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical’s product candidates and that such trials will not meet their endpoints, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2018 and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

First Half 2019 Highlights

Auris Medical
Cochlear therapies

Intranasal Betahistine Program

- Two ongoing clinical trials
- First patient enrolled in Phase 2 trial assessing AM-125 in acute vertigo
- Completion of enrollment of Phase 1b trial assessing AM-201 in antipsychotic-induced weight gain
- Obtained rights to two U.S. patents relating to the treatment of ADHD and depression

Other Development Programs

- Defined development pathway for Keyzilen®
- Actively seeking partners for AM-111

Operational & Financial

- Full repayment of loan facility
- Relocation to Bermuda to reduce costs and better align with U.S. capital market practices
- Regained compliance with Nasdaq minimum bid price requirement
- Completed public offering with net proceeds of $7.6 million



Program Updates

Auris Medical
Cochlear therapies

AM-125: Trial Progressing



Dillon NP et al. (2017), Otol Neurotol. 38(3): 441-7.

- TRAVERS: Multicenter randomized controlled Phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following vestibular schwannoma resection
- Enrolling 138 patients
- Clinical trial sites in several European countries and Canada
- Primary efficacy outcomes: time standing on foam, tandem Romberg test

Milestones

✓First patient randomized in Q3 2019

✓Ramp-up throughout Q3 2019

- Interim analysis in Q4 2019 / Q1 2020

Design of TRAVERS Phase 2 Trial

Part A
N = 50 + 16

- Patients with acute vertigo following vestibular schwannoma resection
- Dose Escalation: 5 steps with AM-125 vs. placebo (t.i.d.)
- Open-label oral betahistine (48 mg)

Interim Analysis

- Determine dose response curve
- Pick two doses for Part B
- Re-assess sample size and powering assumptions for Part B

Part B
N = [72]

- Assess AM-125 high dose and low dose against placebo

AM-201: Trial Progressing



- Phase 1b proof-of-concept trial with AM-201 in antipsychotic-induced weight gain
- Single trial site in Europe
- Enrolled 50 healthy volunteers
- Efficacy outcomes:
  - Primary – reduction in weight gain
  - Secondary – reduction in somnolence

Milestones

✓Recruitment started in Q1 2019

✓Enrollment completed in early July 2019

- Read-out expected in Q3 2019

Design of AM-201 Phase 1b Trial

Auris Medical
Cochlear therapies

Screening

- Healthy male or female volunteers 18-50 years of age
- BMI 18-25 kg/m^2
- Dose escalation: 5 steps with AM-201 vs. placebo (t.i.d.)

Titration OLZ

- Titrate OLZ up to 10 mg (7.5 mg) q.d. within first week
- Subjects who do not tolerate OLZ or who gain clinically relevant amount of weight or high glucose level to be replaced

Maintenance

- Maintain OLZ dose for three weeks

Extension post read-out:

- Option for two more dose cohorts (30 and 40 mg)
- Based on positive safety profile in first five cohorts

Other Betahistine Developments

Auris Medical
Cochlear therapies

Obtained rights to two U.S. patents relating to treatment of two mental disorders

- Closed purchase of two U.S. patents related to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (“ADHD”)
- U.S. patents 8,119,668 and 8,242,148, “Treatment methods employing histamine H3 receptor antagonists, including betahistine,”
- Key claims directed towards the treatment of depression and ADHD, respectively.

Sonsuvi® / AM-111 Update

Partnering Process Ongoing

- Supported by international transaction advisory firm targeting potential partners for AM-111 development program
- Discussions with potentially interested parties ongoing

Keyzilen® / AM-101 Update

Keyzilen
esketamine hydrochloride

- Defined path forward for Keyzilen® / AM-101 program in acute inner ear tinnitus
  - Completed design of new Phase 2/3 trial
    - Phase 2: reaffirm efficacy
    - Phase 3: confirm efficacy to support filing for marketing authorization
  - In-depth analyses of outcomes from TACTT2 and TACTT3 and related AMPACT1 and AMPACT2 trials provide good understanding of issues with elements of design and conduct
- Exploring options for implementation through partnering and / or non-dilutive funding
- Seeking advice / validation from FDA/EMA



Financial Update

Auris Medical
Cochlear therapies

First Half 2019 Financial Update

Auris Medical
Cochlear therapies

Select data from profit and loss account (CHF 1,000)

	6 months ended June 30	
	2019	2018
Research and development*	1,304	4,958
General and administrative	2,803	2,459
Operating loss	4,108	7,417
Net loss	3,604	4,825
Net loss per share (CHF)	1.66	16.36
Average weighted number of shares outstanding	*2,173,307*	*294,914*

** R&D expenses in first half of 2019 were CHF 2.9 million before capitalization of expenses related to the AM-125 program in accordance with IAS38*

First Half 2019 Financial Update

Auris Medical
Cochlear therapies

Select data from balance sheet (CHF 1,000)

	June 30, 2019	December 31, 2018
Cash and cash equivalents	5,792	5,393
Total assets	11,733	9,877
Loan facility	-	1,435
Shareholders' equity	8,952	3,650



Summary and Conclusion

Auris Medical
Cochlear therapies

Upcoming Value-Creating Milestones

Q3 2019	Top-line data AM-201 Phase 1b trial
Q3 2019	Regulatory feedback Keyzilen® / AM-101
Q4 2019 / Q1 2020	Interim data AM-125 Phase 2 trial
Q1 2020	Data from extended AM-201 Phase 1b trial



Take care of your ears!

Auris Medical Holding Ltd.
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
Phone +1 (441) 295 59 50
www.aurismedical.com | NASDAQ: EARS

Auris Medical
Cochlear therapies